Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Resistance's irresistible need

Industry's anti-infective efforts step up a gear

AntibioticsAntimicrobial resistance. It's not, perhaps, a particularly dynamic topic, but it will be a priority one for 2014, at least as far as the EMA is concerned. 

Finalising its 2014 work programme late last year the European regulator made “tackling the issue of antimicrobial resistance and availability of anti-infective treatment options” one of its focus areas for this year.  

The area has gradually been gaining momentum, especially during the last 12 months, beginning in February when EU efforts to combat the issue saw five major pharma firms partner under the auspices of the Innovative Medicines Initiative's (IMI) New Drugs for Bad Bugs programme.  

As bacterial infections grow increasingly resistant to current treatments, leaving doctors with fewer options, individual companies have made progress on researching new antibiotics.  

Cubist looks to be on track to file its new antibiotic later this year after posting positive phase III data in December and AstraZeneca, despite planning to cut back on its anti-infectives research, forged a new partnership in November with Singapore's main research centre.  

As was noted on PMLiVE recently, the discovery of antibacterial drugs was a transformative moment in human history, but increasing resistance demands a global commitment to develop new drugs. Clearly, when antimicrobial resistance still causes 25,000 deaths each year, the need for pharma successes in this area is irresistible.

Article by
Dominic Tyer

editorial director of PMGroup

14th January 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics